Abstract 1581 Poster Session II, Sunday, 5/2 (poster 117)
Objective. To examine whether the determination of IL-8 and CRP in neonates with suspected NBI is safe, feasible, and cost-effective in reducing antibiotic therapy. Methods. Between April 1996 and May 1997, IL-8 was measured 260 times along with blood cultures, CRP and Immature-to-Total-Neutrophil-Ratio (IT-ratio) for suspected NBI in term and preterm neonates. All infants were retrospectively analyzed for NBI. Sensitivity, specificity, positive and negative predictive values, and 95% confidence intervals were calculated for IL-8, CRP and IT-ratio. Receiver-operating characteristic (ROC)-curves were analyzed to determine optimal thresholds. Between June 1997 and June 1998, IL-8 was measured 215 times in newborn infants with suspected NBI and the decision to start antibiotic therapy was based on increased IL-8 and/or CRP values. Patient outcome was monitored, a cost-effectiveness analysis was performed and sensitivity, specificity, ROC-curves were reevaluated. The diagnosis of 'culture-proven NBI' was based on clinical signs and positive blood or cerebrospinal fluid cultures, that of 'clinical NBI' on clinical signs and a CRP > 10mg/l 12-60 hours after initial evaluation. Results. At the first suspicion of NBI, the combination of IL-8 ≥53pg/ml and/or CRP ≥ 10 mg/l detected culture-proven NBI with 96% (100%) sensitivity in the first (second) study period. The combined culture-proven and clinical NBI were detected with 93% (100%) sensitivity and 80% (83%) specificity. Using IL-8 reduced 'unnecessary' antibiotic therapy for suspected NBI by 73% and was cost-effective. No NBI related adverse outcome was observed in the second study period despite delaying antibiotic therapy until IL-8 and CRP were available. Conclusions. The combination of IL-8 and CRP is a reliable and early test for the diagnosis of NBI in neonates. It allows to restrict antibiotic therapy to truly infected infants, and to safely reduce 'unnecessary' antibiotic therapy and costs.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Axel, R., Steinbach, G., Kron, M. et al. Safe Reduction of Antibiotic Therapy in Newborn Infants Using Interleukin 8 (IL-8) and C-Reactive Protein (CRP) as Markers of Nosocomial Bacterial Infections (NBI). Pediatr Res 45, 269 (1999). https://doi.org/10.1203/00006450-199904020-01598
Issue Date:
DOI: https://doi.org/10.1203/00006450-199904020-01598